Skip to main content

BRM 2020 - Business of Regenerative Medicine

 

Business of Regenerative Medicine

Business of Regenerative Medicine

THE 2020 MEETING HAS BEEN CANCELLED due to the COVID-19 pandemic. 
Dates for the 2021 meeting to be held at Georgia Tech will be announced soon!


About the program

The Business of Regenerative Medicine conference returns to the Parker H. Petit Institute for Bioengineering and Bioscience at the Georgia Institute Technology with the theme for 2020: Transforming the Manufacture of Regenerative Medicine Products.

This 13th annual edition of the conference will bring together biotechnology thought leaders for three days of panel discussions, presentations, and networking at one of the nation’s leading academic research institutions, and home of the National Science Foundation Research Center for Cell Manufacturing Technologies (CMaT).

Topics such as 3D printing, gene editing, automation, logistics, and policy will be discussed from some of the field's top experts: Amy Patterson (NHLBI, NIH), Jeff Hubbell (University of Chicago), Scott Hollister (Georgia Tech), Heather Prichard (Humacyte), as well as best-selling author Kelli Harding (The Rabbit Effect: Live Longer, Happier, and Healthier Lives with the Groundbreaking Science of Kindness). Together with panel discussions on reimbursement, bioethics, and entrepreneurship, these speakers and presentations will clarify the value, and transformative potential, of regenerative medicine.

This is a unique opportunity to meet with industry executives, venture capitalists, clinicians, biomedical researchers, patient advocates, and other industry experts at the 13th annual Business of Regenerative Medicine conference in Atlanta, one of the nation’s leading hubs of biomedical research.


When and where

Monday, June 1–Wednesday, June 3, 2020
Georgia Tech, GA

 

About the organizers

The annual Business of Regenerative Medicine conference is organized and managed collaboratively by the Parker H. Petit Institute for Bioengineering and Bioscience at Georgia Tech, Case Western Reserve University, Centre for Commercialization of Regenerative Medicine (Toronto), the Harvard Stem Cell Institute at Harvard University, and the Penn Institute for Regenerative Medicine/Penn Medicine Center for Cellular Immunotherapies at University of Pennsylvania.